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Heterologously expressed serotonin 1A receptors couple to
muscarinic K+ channels in heart
(vaccinia virus expression/guanine nucleotide-binding proteins/seven-helix receptors/atrial cells/acetylcholine)
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ABSTRACT In cardiac atrial cells, muscarinic acetylcho-
line receptors activate a K+ current directly via a guanine
nucleotide-binding protein (G protein). Serotonin type 1A
receptors may activate a similar pathway in hippocampal
neurons. To develop a system in which receptor/G protein/K+
channel coupling can be experimentally manipulated, we have
used a highly efficient recombinant vaccinia virus vector system
to express human serotonin 1A receptors in primary cultures
of rat atrial myocytes. The expressed 1A receptors activated the
inwardly rectifying K+ conductance that is normally activated
by the endogenous muscarinic acetylcholine receptors. Maxi-
mal responses to either agonist occluded further activation by
the other agonist. The average activation time constants for
serotonin were about 5 times slower than for acetylcholine. The
data support suggestions that the intracellular signaling path-
way from seven-helix receptors toG proteins and directly to ion
channels is widespread in excitable cells. After a fraction of the
G proteins are activated irreversibly by guanosine 5'-(y-
thioltriphosphate, subsequent transduction proceeds more ef-
ficiently. One possible interpretation is that multiple G-protein
molecules are required to activate each channel. Vaccinja virus
expression vectors are thus useful for expressing seven-helix
receptors in primary cultures of postmitotic cells and have
provided a heterologous expression system for the signaling
pathway from seven-helix receptors to G proteins and directly
to ion channels.
After an appropriate agonist binds to any of the several
seven-helix receptors, a guanine nucleotide-binding protein
(G protein) is activated. In most known cases, the G protein
then activates or inhibits an enzyme, and cell function
changes within a few seconds. An alternative signaling path-
way, which was first observed for muscarinic acetylcholine
receptor (mAChR) stimulation of cardiac atrial cells, is direct
activation of an ion channel by a G protein (1-5); in this
pathway, cell function can be altered within 100-300 ms (6,
7). Indirect evidence suggests that several additional classes
of receptors, G proteins, and ion channels participate in such
a direct, relatively rapid receptor/G protein/ion channel
pathway in a variety of excitable cells. Candidate receptors
include serotonin (5-hydroxytryptamine, 5-HT) 1A, ,u or 8
opioid, adenosine A1, y-aminobutyrate GABAB, dopamine
D2, somatostatin, and a2-adrenergic receptors (8-11). Strong
evidence for this suggestion would come from the demon-
stration that the several protein components of this pathway
retain sufficient similarity to allow efficient and rapid signal-
ing in a reconstituted system with receptors, G proteins, and
ion channels from different cells of origin. Indeed, in inside-
out patches, guanosine 5'-[y-thio]triphosphate (GTP[yS])-
stimulated Gia subunits can directly activate (12) the in-
wardly rectifying K+ channels normally activated by
mAChRs, and probably adenosine A1 and somatostatin re-
ceptors (13, 14), in atrium. We therefore sought to express an
additional seven-helix receptor in atrial cells and tested for
functional coupling to the endogenous K+ conductance.
It has been reported that 5-HT type 1A receptors (5-
HT1ARs) are coupled in various cells both to inhibition of
forskolin-stimulated adenylate cyclase (15, 16) and to its
stimulation (17). However, the latter conclusion has been
criticized (16). In a heterologous system, stimulation of
phospholipase C and inhibition of adenylate cyclase have
been reported (18). We chose the 5-HT1AR for heterologous
expression because of the evidence that it can activate Gi and
because it has been reported to activate K+ channels in
hippocampal neurons by a pertussis toxin-sensitive G protein
and without soluble cytoplasmic intermediates (19).
The most appropriate host cell was the atrial myocyte,
because (i) the direct receptor/G protein/K+ channel path-
way has been demonstrated most conclusively for this cell
and (ii) although several techniques have been developed for
stable expression of foreign proteins in clonal cell lines,
inwardly rectifying G-protein-activated K+ channels are not
presently known in any cell lines. A previous study (20)
showed that the vaccinia virus (VV) system allows for
heterologous expression of K+ channels in primary cultures,
including atrial myocytes, at a density of 1 to 5 channels per
Am2. However, it was expected that higher expression levels
would be required for seven-helix receptors in the pathway
that involves direct coupling from G proteins to ion channels.
In bullfrog atrial cells the average density of mAChRs (-170
per pum2 ofcell membrane) exceeds that ofK+(ACh) channels
by -200-fold (21); in AtT-20 lactotrophs the ratio of somato-
statin S-14 receptors to K+ channels is -130 (22). We have
therefore adapted a highly efficient variant of the vaccinia
system for expression of the 5-HT1AR.
MATERIALS AND METHODS
Construction of a Recombinant Virus Encoding the
5-HTIAR. For the construction of the recombinant plasmid
pTM1-5HT1AR, the start codon of the 5-HT1AR gene was
inserted into an Nco I site of the VV insertional vector pTM1
(23) to correspond to the initiating ATG codon in the se-
quence of the encephalomyocarditis virus (EMCV). There-
fore, a Dde I-BamHI fragment (1.29 kilobases) within the
coding region of the 5-HT1AR gene was excised from pSVL-
5HT1AR and ligated to a synthetic 5' Nco 1/3' Dde I adaptor
Abbreviations: 5-HT, serotonin (5-hydroxytryptamine); 5-HT1AR,
serotonin type 1A receptor; ACh, acetylcholine; mAChR, muscar-
inic ACh receptor; G protein, guanine nucleotide-binding protein;
GTP[yS], guanosine 5'-[y-thio]triphosphate; VV, vaccinia virus.
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that contained the sequence between the start codon and the
Dde I site of the receptor coding region. pTM1 was digested
with Nco I/BamHI, dephosphorylated, and ligated to the
adaptor/5-HTlAR fragment. The recombinant plasmid
pTM1-5HTlAR, amplified in Escherichia coli JM109 and
purified by CsCl centrifugation, was inserted into the VV
genome by homologous recombination in vivo. Thymidine
kinase-negative L (Ltk-) cells were infected with wild-type
VV (WR strain from the American Type Culture Collection)
at low multiplicity of infection (0.05 plaque-forming unit per
cell) and subsequently transfected with pTM1-5HTlAR. Af-
ter amplification in medium containing 5'-bromodeoxyuri-
dine, successful recombinants were isolated by several
rounds of plaque hybridization and grown to large scale (24).
Infection of Atrial Myocytes. Atrial myocytes were disso-
ciated from the atria of rats at postnatal day 2 or 3 by using
collagenase (25) and were incubated for 24-48 hr before
infection. Cultures were simultaneously infected with the
helper virus vTF7-3 and VV:5HT1AR (multiplicity of infec-
tion 10 each) for 30 min at room temperature, the virus
inoculum was exchanged for medium, and the cells were
incubated for 12-24 hr. Precautions were observed to prevent
accidental exposure of personnel and to inactivate all virus
before disposal.
Electrophysiological Recordings. Infected cells on cover-
slips were washed three times with Tyrode bath solution (135
mM NaCl/5.4 mM KCl/1.8 mM CaCI2/1 mM MgCl2/10 mM
Hepes/5 mM glucose, pH 7.4). Patch pipettes for whole-cell
recording (26) were pulled from Kimax borosilicate glass
tubing and heat-polished to give input resistance values of
4-7 MW. The intracellular pipette solution was 140 mM
KCl/2 mM MgC12/1 mM EGTA/5 mM Hepes/1 mM
Na2ATP/0.1 mM cAMP/200 uM GTP, pH 7.3. Currents
were measured at room temperature (19-22°C) with a
DAGAN 8900 (Dagan Instruments, Minneapolis) patch
clamp and low-pass-filtered at 3 kHz. Stimulation, data
acquisition, and analysis were performed using PCLAMP soft-
ware (Axon Instruments, Foster City, CA) on an IBM PC.
Agonist-induced currents were isolated by digitally subtract-
ing capacitive transients and records in the absence of
agonists. Drugs were applied from a fast flowpipe microper-
fusion system consisting ofseven polyethylene tubes (each of
150-,um internal diameter). The parallel array of tubes was
mounted on a micromanipulator and 100-150 Am from the
cells. Change of solutions using this system was measured
using K+ concentration jumps in the presence of agonist and
occurred in <50 ms.
Binding Assay. Ligand binding was performed (27) with
lysed membranes in 50 mM Tris/1 mM MnCl2, pH 8.2, for 60
min at room temperature. Nonspecific binding was deter-
mined in the presence of 10 /,M 5-HT.
RESULTS
To obtain expression of the 5-HT1ARs at levels (21, 22)
approaching those of the endogenous mAChRs (>100 per
uM2), we used a novel high-efficiency expression system
based on infection with two recombinant VVs (Fig. 1) (23).
One VV (vTF7-3) had been engineered to express the bac-
teriophage T7 RNA polymerase gene under the control of the
early/late P7.5 vaccinia promoter (28). The second virus
(VV:SHT1AR) carried (from 5' to 3') the T7 RNA polymerase
promoter (4' 10) and hairpin sequence, the 5' untranslated
region from encephalomyocarditis virus, the coding region of
the human 5-HT1AR gene (29), and the T7 terminator se-
quence (T4). In experiments to test the efficiency of expres-
sion, BSC-40 cells, COS-7 cells, and GH3 cells were coin-
fected with vTF7-3 and VV:SHT1AR. Specific binding of
tritiated 5-HT and 8-hydroxy-2-dipropylaminotetralin re-
vealed -3 pmol/mg of membrane protein, corresponding to
W:5HT1AR
5HT1AR
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atrial myocytes
after 1 8 hr
vTF7-3
FIG. 1. Coinfection procedure for high-level expression of
5-HTlARs in atrial cells using two recombinant VVs. 410 and T4,
phage T7 RNA polymerase promoter and terminator sequences;
P7.5, P7.5 vaccinia promoter. See Materials and Methods for further
explanation.
=1.5 x 105 5-HTlARs per COS-7 cell (or 85 per ,gm2 of cell
membrane, if most of the receptors are on the plasma
membrane).
When noninfected control cells were voltage-clamped with
the external K+ concentration ([K+Jo) raised to 25 mM,
application ofACh (5 ,uM) from a fast microperfusion system
induced prominent inward currents with amplitudes of -655
± 92 pA (mean ± SEM; n = 23) at -90 mV. Application of
5-HT (5 ,uM) in these control cells never elicited any detect-
able responses (n = 25; Fig. 2A). In contrast, 12-18 hr after
atrial myocytes were coinfected with the helper virus vTF7-3
and VV:5HT1AR, they responded with an inward current
upon application of both ACh (-628 ± 91 pA; n = 17) and
5-HT (-288 ± 30 pA; n = 17; Fig. 2B). Some of the infected
atrial cells were still beating but were identified by distinct
morphological changes, such as rounding up and cytoplasmic
inclusions. Approximately 30% of the 224 obviously infected
cells that were studied responded to 5-HT. Voltage ramp
recordings in the presence of both ACh and 5-HT (Fig. 2 C
and D) showed strong rectification for inward currents,
negative to the equilibrium potential for K+ (EK = -43 mV).
The inwardly rectifying current induced by both agonists was
highly selective for K+, since the reversal potential decreased
with increasing [K+]o and was close to EK, as predicted by the
Nernst equation. In a different voltage protocol the mem-
brane potential of infected atrial cells was stepped to hyper-
polarizing levels in the presence of the agonists and the
current responses were plotted against the step potentials
(Fig. 2E). Again the current/voltage (I/V) relations for the
action ofACh and of5-HT in the same cell were identical and
inwardly rectifying. In addition, the voltage jump relaxations
for the two agonists exhibited the same time constants (r =
19 ms at VY = -120 mV), similar to the value reported
previously for IK[Achl in frog and guinea pig atrial cells (30,
31). Current with this characteristic I/V relationship in coin-
fected cells could be mimicked by the selective 5-HT1AR
agonist 8-hydroxy-2-dipropylaminotetralin. These results in-
dicate that in coinfected atrial cells, newly expressed
5-HT1ARs mediate the activation of a K+ conductance iden-
tical or very similar to the endogenous current IK[ACh1, which
is activated by ACh.
In an additional series of experiments using 5- or 10-s
pulses of agonists between 0.05 and 50 ,M, we studied
occlusion of the responses. Concentration-response rela-
tions revealed half-maximal concentrations of 0.36 ,uM for
ACh and 0.11 AM for 5-HT and desensitization in responses
to concentrations above 25 ,uM (Fig. 3A). A maximal re-
sponse evoked by either one of the two agonists (5 AM)
occluded additional increases during application of the other
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FIG. 2. After coinfection with vTF7-3
p00pA and VV:5HT1AR, atrial myocytes respond12a to 5-HT with a current that corresponds to
IK[AChI- Cells were voltage-clamped at -90
mV (A and B), or stimulated with a voltage
ramp between -120 and +60 mV (C and D)
Cointectd and [K+Jo was raised to 25 mM. Horizontal
bars indicate the time of drug application. (A
0 l---- sitszI- and C) Noninfected cells and cells infected
with wild-type VV (data not shown) respond
.4*qACh | to ACh (10 jLM) but not to 5-HT (10 .M) with
'~h an inwardly rectifying current. (B and D)
.8 .@ Coinfected cells after 14 hr respond to both
.2 agonists with current primarily in the inward
1 1.,20 direction. (E) Superimposed current/volt-
.6 age relationship for whole-cell currents in-
duced by ACh and 5-HT, measured at the
-150 -110 -70 -0 10 50 end of 200-ms hyperpolarizing voltage steps
Voltage (mV) from -30 mV to -120 mV.
agonist (Fig. 3B), which suggests that the two agonists
compete for the same component in the receptor/G pro-
tein/K+ channel pathway. Thus, both the endogenous
mAChRs and the VV-expressed 5-HT1ARs converge onto the
same population of K+ channels.
The activation ofIK[AChI appears to be mediated directly by
a G protein, probably a Gia subunit (12, 32), independently
of any difussible cytoplasmic messengers. Strong evidence
for direct coupling was provided by (i) measurements on
single channels in excised cell-free membrane patches from
atrial muscle (4, 5) and (ii) the rapid time course of activation
and deactivation. The current evoked by ACh (5 AtM) in our
preparation activated with a time constant of Tact = 317 + 12
ms (n = 32), in agreement with previous data (6, 7). The
ACh
0.8- 11002550
0.4- 1 1 1
0.2
0 0.5 1 2 3 4 5
Concentration (pjM)
0
_
-100 -
-300 -
ACh
ACh ACh + S-HT
0
deactivation time constant was Tdeact = 965 + 75 ms (n = 23;
Fig. 4B). Interestingly, current responses mediated by the
expressed 5-HTlARs in coinfected atrial cells (5 uM 5-HT)
showed similar deactivation rates upon removal of the ago-
nist, with Tdeact = 924 + 39 ms (n = 16), but in addition to the
typically smaller current amplitudes, more variable and usu-
ally slower activation time constants, Tact = 1682 + 180 ms (n
= 12; Fig. 4B), were observed.
The different activation rates for ACh and 5-HT responses
could arise from the probable lower density of 5-HT recep-
tors or from another mechanism, such as a less effective
receptor/G protein association. To investigate this difference
further, we uncoupled the receptors from the rest of the
pathway by internally perfusing the nonhydrolyzable GTP
5-HT
_--1--.----------------------------------------
CDa) 0.8- s 0.1 0.5 1 5 10
00.6
> 0.4
0 0.5 1 2 3 4 5
Concentration (uM)
5-HT_,s-
-100-
0 12 24
Time (s)
FIG. 3. Maximal responses to 5-HT and ACh
occlude each other. (A) Concentration-response
relationships for both ACh and 5-HT in two differ-
ent coinfected atrial cells. Data represent the mean
+ SEM of normalized current amplitudes ('max =
response to 25 ,M agonist) of four cells each. The
raw traces are consecutive current responses, at a
holding potential of -90 mV, to 5- or 10-s pulses of
each agonist (in AM). Scale bars: 500 pA (ACh), 100
pA (5-HT), 10 s. The curves are the best fit of the
data to I = Imax X [agonist]/(EC5o + [agonist]) with
EC50 = 360 nM (ACh) or 110 nM (5-HT). (B) When
a maximal current response is induced by ACh (5
AM), additional application of 5-HT (5 AuM) in a
coinfected atrial cell produces no further response,
and vice versa. Superimposed line represents the
expected response if the two responses were inde-
pendent of each other and additive.
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FIG. 4. Intracellular perfusion ofGTP[yS] indicates the involvement ofaG protein for the actions of both ACh and 5-HT (5 tLM) in coinfected
atrial cells. (A) Persistent activation of IK[AChJ by GTP[yS]. Neither agonist produces a significant response after complete activation of IK[AChl
with 500/50 jLM internal GTP[yS]/GTP. (B-D) Kinetic analysis of the activation and inactivation rates of the currents induced by both agonists.
The traces in B represent typical responses to 5-HT and ACh in a cell perfused with 200 ,uM GTP. Activation time constants (Tact) are 1250 ms(5-HT) and 300 ms (ACh); inactivation time constants (m,,,ct) are 1100 ms (5-HT) and 1020 ms (ACh). Intracellular perfusion with GTP[yS]/GTP(1/0.2 mM) changes the onset and offset rates of IK[AChj for both agonists, even before persistent current activation develops fully. In C, for
5-HT-induced currents: Tact = 1490 ms (0 min), 550 ms (1 min); Tiact = 920 ms (0 min), 1950 ms (1 min). Response to ACh recorded 20 s earlier
is superimposed (dotted line). In D, for ACh-induced currents: Tact = 340 ms (0 min), 195 ms (1 min); Tinact = 1500 ms (0 min), 4700 ms (1 min).
Exponential fits on the right are normalized in amplitude; the traces marked with an asterisk represent recordings taken at later times.
analog GTP[yS] through the patch pipette. The experiments
revealed two different time-dependent processes. First, as
expected, a persistent activation of IK[ACh] by GTP[yS]
developed slowly over several minutes, even in the absence
of the agonists (33). After this persistent activation by
GTP[yS] reached a plateau, addition ofACh or (in coinfected
cells) 5-HT produced only a small additional current (Fig.
4A), demonstrating that an activated G protein can open the
same channel. The time required for complete activation of
receptor-independent IK[AChI varied from 4 to 20 min depend-
ing on the GTP[yS]/GTP ratio (2:1 to 10:1) in the pipette
solution and on whether agonists had been applied intermit-
tently (33).
A second, unexpected set of phenomena occurred at early
stages during the perfusion with GTP[yS]. There was (i) an
increase in the rate of current activation and (ii) a decrease
in deactivation rate in response to either agonist (Fig. 4 B-D)
and (iii) especially for 5-HT, an increase in current amplitude.
These effects were never observed when GTP[yS] was absent
from the internal solution. GTP[yS] perfusion dramatically
increased the typically slow and small responses mediated by
the heterologously expressed 5-HT1ARs. In a minority of
cells, extremely slow 5-HT-induced responses (Tact > 3000
ins) developed amplitudes and kinetics similar to the currents
elicited by the same concentration ofACh (ract < 500 ms). We
emphasize that the measurements on heterologously ex-
pressed 5-HTIARs readily revealed a kinetic effect that is also
present for the endogenous muscarinic response. With both
ACh and 5-HT, the faster activation corresponds to an
increase of 1-2 s-1 in the rate constant for activation.
DISCUSSION
The present data, showing that human 5-HT1ARs couple to
the muscarinic pathway in rat atrial myocytes, confirm the
suggestion that 5-HT1ARs couple to K+ channels via a direct
G protein-channel interaction. The occlusion data show that
the newly expressed 5-HT1ARs activate the same K+ chan-
nels as the endogenous muscarinic AChRs, thus suggesting
that they activate very similar G proteins.
Because the experiments employed the high temporal reso-
lution of electrical recordings, they also showed (i) that, under
the conditions used, activation by 5-HT proceeds more slowly
than activation by ACh and (ii) that deactivation proceeds at
about the same rate. These kinetic phenomena were studied
further, and an additional effect was noted. After a fraction of
the G proteins are activated irreversibly by GTP[yS], subse-
quent transduction proceeds more efficiently. This effect was
present for both the endogenous ACh responses and for the
newly expressed 5-HT responses. In present schemes for
activation of this pathway, an activated receptor promotes
nucleotide exchange at the heterotrimeric Gk protein and sub-
sequent dissociation into GTP-activated a[GTPJ and 83y sub-
units. The finding that irreversible G-protein activation by
GTPII'yS] enhances the efficiency of transduction by a subse-
quent pulse of agonist could be interpreted in a straightforward
fashion if the channel required interaction with several (n)
a[GTP] subunits rather than with a single one. We cannot
definitely state the identity ofthe rate-limiting step for activation
ofthe channel; it could be: (i) GDP/GTP exchange, (ii) a[GTP}-
fry dissociation, or (iii) diffusion of the activated a subunit
toward the channel. What is important is that this rate-limiting
step is eliminated for a Ga subunit that has GTP[yS] bound to
it. As time passes in the presence of GTP[yS], more and more
of the n Ga subunits required to activate a single channel
become activated. With subsequent agonist applications, fewer
Ga subunits need to undergo the rate-limiting step and activa-
tion becomes more rapid. Eventually, when all n Ga subunits
for a given channel are irreversibly activated, the channel
becomes permanently activated.
Neurobiology: Karschin et al.
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In this model, the channel closes upon GTP hydrolysis at
any of the n independent subunits associated with it. Thus the
rate of channel closing decreases as the Ga subunits become
permanently bound with GTP[yS]. When only 1 of the n Ga
subunits retains GTPase activity, the channel deactivation rate
decreases by n-fold from the value with all subunits able to
hydrolyze GTP. For the data in Fig. 4, n is in the range 2-4;
for all of our averaged data, n = 2.9. This model invites
speculation that the channel, like many voltage-dependent K+
channels, has n independent subunits, each capable of inter-
acting with a Ga subunit. The model predicts a nonlinear
dependence of IK[AChl on guanine nucleotide concentration.
Such an effect might have escaped notice in the past because
of technical difficulties in accurately controlling the rather low
GTP concentrations (Km - 10-7 M) involved. Recent studies
do suggest that the dependence of activation on guanine
nucleotide concentration is characterized by a Hill coefficient
of 2-3 (33, 34). A detailed scheme involving these ideas must
also account for the Hill coefficient near 1 usually observed for
activation of IK[ACh] (see also Fig. 3A). Other mechanisms for
the effects of hydrolysis-resistant GTP analogs-e.g., involv-
ing GTPase-activating proteins (35), arachidonate metabolites
(36, 37), and 8y subunits-are possible.
It was previously suggested that activation ofK+ channels
by muscarinic receptors involves several independent but
identical rate-limiting steps (6, 38). Our experiments suggest
that these steps might involve multiple G-protein molecules
interacting with a single channel.
We may ask whether ACh acting on atrial mAChRs and
5-HT on the heterologous 5-HT1ARs activate the same set of
G proteins. Yatani et al. (12) have shown that in inside-out
atrial patches, Gial, Gja2, and Gja3, when activated by
[GTPyS], all efficiently stimulate the same K+ channels.
Activated Gsa was not effective, and G~a, as purified,
stimulated about 5% as effectively as did any Gia (4). There
is compelling evidence that 5-HT1ARs do activate G1 (i.e.,
inhibit forskolin-stimulated adenylate cyclase activity) in a
number of cell types (15, 16, 18); in a heterologous expression
system, they are also coupled to phospholipase C, albeit with
an =50-fold higher EC50. Coupling to phospholipase C may
be mediated by G. (39). We conclude that the principal
pathway for 5-HT1AR stimulation of the K+ current is via
direct ligand activation by one or several atrial Gia isoforms,
all of which are expressed in human atria (40).
VV vectors presently provide the most appropriate heter-
ologous expression system for postmitotic vertebrate cells in
primary culture. Because VV directs expression in a high
percentage of the cells in a given culture, this system is well
suited for expression for single-cell studies. VV systems may
prove useful for reconstitution of the entire functional seven-
helix/G protein/ion channel pathway.
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